Heterogeneidade das formas carboxi-terminal circulantes de paratormônio em pacientes com hiperparatiroidismo devido à insuficiência renal crônica terminal by Vieira, José Gilberto H. et al.
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
Arq Bras Endocrinol Metab. 2009;53/91074
original article
Heterogeneity of carboxyl-terminal 
parathyroid hormone circulating forms 
in patients with hyperparathyroidism 
due to end stage renal disease
Heterogeneidade das formas carboxi-terminal circulantes 
de paratormônio em pacientes com hiperparatiroidismo 
devido à insuficiência renal crônica terminal
José Gilberto H. Vieira1, Ilda S. Kunii1, Monique N. Ohe1, Aluizio B. Carvalho2
AbstrAct
Objective: To study carboxyl-terminal (COOH) parathyroid hormone (PTH) circulating forms 
in patients with hyperparathyroidism due to end stage renal disease (ESRD). Methods: An im-
munometric assay that recognizes both intact and COOH PTH forms was developed. The assay, 
in conjunction with an intact assay, was used to measure PTH in serum samples obtained from 
25 patients with hyperparathyroidism due to ESRD. Samples were also submitted to gel filtra-
tion chromatography in a Superdex® 30 1.6 x 60 cm column, and the PTH content in the elution 
tubes, measured using both assays. Results: Values from 39.000 to 232.300 ng/mL (mean ± sd 
= 101.680 ± 45.330 ng/mL) were found using the COOH assay (PTH 39-84 was used as standard). 
Values obtained by the intact PTH assay ranged from 318 to 3.307 ng/mL (1.769 ± 693 ng/mL) with 
a correlation between assays of 0.462 (p = 0.02). The elution profile obtained using the COOH 
assay showed a preponderance of forms with MW ranging from 8.500 to 4.500 daltons. The 
profiles obtained from the 25 patients were very similar. Conclusions: In patients with hyper-
parathyroidism due to ESRD circulating PTH levels contain a broad range of molecular forms 
including COOH with MW ranging from 8.500 to 4.500 daltons. These forms are not recognized 
by the standard intact PTH assays. The correlation of these findings to the clinical aspects of 
bone disease in ESRD patients remains to be studied. Arq Bras Endocrinol Metab. 2009;53(9):1074-8
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resumo
Objetivo: Estudar as formas carboxi-terminal (COOH) circulantes de paratormônio (PTH) em pa-
cientes com hiperparatiroidismo devido à insuficiência renal crônica (IRC) terminal. Métodos: Foi 
desenvolvido um ensaio imunométrico que reconhece formas intactas e COOH longas de PTH. 
Esse ensaio foi utilizado, em conjunto com um ensaio para molécula intacta de PTH, em amostras 
de 25 pacientes com hiperparatiroidismo devido à IRC. As amostras também foram submetidas à 
cromatografia de gel filtração em coluna de Superdex® 30 de 1,6 x 60 cm, e o conteúdo de PTH nos 
tubos de eluato foi medido, empregando-se os dois ensaios. Resultados: Valores entre 39.000 e 
232.300 ng/mL (média ± dp = 101,680 ± 45,330 ng/mL) foram obtidos usando-se o ensaio COOH 
(PTH 39-84 foi utilizado como padrão). Com o ensaio para PTH intacto, os valores distribuíram-
se entre 318 e 3,307 ng/mL (1,769 ± 693 ng/mL) com correlação entre ambos de 0,462 (p = 0,02). 
O perfil cromatográfico obtido com o ensaio COOH mostrou predomínio de formas com PM entre 
8.500 e 4.500 daltons. Os perfis cromatográficos dos 25 pacientes foram bastante semelhantes. 
Conclusões: Em pacientes com hiperparatiroidismo devido à IRC, os níveis circulantes de PTH 
contêm um espectro de formas moleculares que incluem formas carboxi-terminais, com PM en-
tre 8.500 e 4.500 daltons. Essas formas não são reconhecidas pelos ensaios de rotina utilizados 
para a medida de PTH intacto. A correlação entre esses achados e os aspectos clínicos da doença 
óssea em pacientes com IRC necessita de maiores estudos. Arq Bras Endocrinol Metab. 2009;53(9):1074-8
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IntroDuctIon
Parathyroid hormone (PTH) is a linear 84 amino acid 
peptide secreted by the parathyroid glands. The biolo-
gical activity of PTH, defined by binding to the classical 
PTH1 receptor (PTH1R), depends on the integrity of 
the amino-terminal sequence of the peptide, mainly its 
first four amino acids (1). 
Methods for measuring circulating PTH have evol-
ved significantly since the introduction of the first ra-
dioimmunoassay in 1963 (2,3). Several competitive 
immunoassays were described during the 1970’s and 
1980’s. Reference ranges as well as diagnostic sensitivity 
and specificity obtained with those assays were markedly 
different. The differences mirrored the wide spectrum 
of circulating forms of PTH recognized by the seve-
ral polyclonal antibodies used in the competitive assays. 
With the description, in the late 1980’s, of the so-called 
“second-generation non-competitive immunometric 
assays” (“sandwich”-type), supposedly measuring only 
“intact” PTH (sequence 1-84), there was a clear impro-
vement of diagnostic sensitivity and specificity, as well as 
a better standardization of assay results (4). 
Nonetheless, new studies suggested that, in some 
clinical circumstances, mainly in patients with end stage 
renal disease (ESRD), additional molecular forms, be-
sides the sequence 1-84, were also measured by these 
intact PTH assays (5). Included were carboxyl-terminal 
(COOH) fragments lacking only the first amino-terminal 
amino acids (e.g. peptide 7-84), also known as “long” 
COOH fragments. These forms are part of a broad 
spectrum of COOH-terminal forms which includes the 
quantitatively more important shorter forms (not recog-
nized by the second-generation assays), known to cir-
culate in high concentration in patients with ESRD (6).
Later “third-generation” assays were introduced (7) 
based on the employment of amino-terminal specific 
antibodies with strict specificity for the first four amino 
acids of the PTH molecule. Consequently, they measu-
re only the bioactive molecule, via PTH1R, PTH-(1-84). 
These observations brought the possibility that, main-
ly in patients with ESRD, results with better correla-
tion to PTH action (via PTH1R) would be obtained 
with these third-generation assays (7). In patients with 
ESRD, the new assay could mean a more specific tool 
for measuring PTH action on bone cells, since, in these 
patients, PTH is used as a surrogate marker for me-
tabolic bone disease. Some publications showed that 
this could indeed be the case, in special if one measures 
PTH using both second- and third-generation assays 
and use both results to calculate a relationship between 
the PTH1R active ((1-84)-PTH) and non-active ((7-
84)-PTH) forms (8). In spite of all logic behind this 
approach, other publications, from several reference 
centers, showed that correlation between bone status 
and PTH measurements in patients with ESRD was si-
milar using third- or second-generation assays (9,10). 
The same observation stands for the 1-84/7-84 PTH 
ratio. Furthermore, correlation between PTH values 
obtained with third- and second-generation assays are 
good, even in patients with ESRD. 
One important point concerning the physiological 
role of the COOH-terminal PTH forms are the recent 
publications by the group of Bringhurst and cols. (11-13) 
showing that these peptides have biological actions that 
are independent of activation or blocking of PTH1R. 
More importantly, a putative C-PTH receptor can be 
activated by forms shorter than PTH-(7-84). These in-
clude PTH-(24-84) and, even, albeit with less affinity, 
PTH-(39-84). These findings can have important im-
plications on the biological meaning of the third- and 
second-generation PTH ratio measurement in ESRD 
patients. Since second-generation assays are usually ba-
sed on antibodies that recognize epitopes in the amino-
terminal region that are not present in most of these 
COOH-terminal PTH forms, they may be not measu-
red by standard intact second-generation assays. 
In this paper, we describe an immunofluorometric 
assay that recognizes an ample spectrum of COOH-
terminal forms of PTH. The levels of PTH found in 
patients with ESRD using the assay are compared with 
those obtained using an intact (second-generation) 
PTH assay. We also present the results obtained using 
both assays to measure PTH immunoreactivity in the 
eluate obtained by applying serum samples of ESRD 
patients to a gel filtration chromatography column. 
methoDs
samples 
Twenty-five dialysis patients with ESRD submitted to 
parathyroidectomy in order to control severe hyperpa-
rathyroidism were studied. Blood samples were collec-
ted just prior to surgery and serum samples stored at 
-20 °C until studied. The protocol was approved by the 
Ethics Committee of our institution (Escola Paulista de 
Medicina, Universidade Federal de São Paulo) and was 
part of a large study on surgical and parathyroid tissue 
autotransplantation optimization protocols.
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cooh assay
To measure COOH-terminal forms of circulating PTH, 
an immunofluorometric assay based on monoclonal 
and polyclonal antibodies was developed. The mono-
clonal antibody (H5P10) was produced by conventio-
nal fusion protocol based on mice immunized against 
synthetic human PTH-(53-84) and its specificity was 
directed against the region around amino acids 68-69 
(14). The polyclonal antibody was developed in rabbits 
immunized against bovine PTH and had a broad speci-
ficity, including amino and COOH-terminal regions of 
human PTH. In the assay design, the COOH-terminal 
specific monoclonal antibody is adsorbed to a solid pha-
se (microtiter plates, FluoroNunc™, Nunc, Roskield, 
Denmark) at 10 µg/mL in PBS, 20 mM, pH 7.4 (200 
µL/well). After an overnight incubation at 4 °C, the 
plates are washed and, in order to lower nonspecific 
binding, treated with 200 µL/well of TrisHCl 50 mM 
solution containing 0.5% bovine albumin and 0.05% 
bovine γ-globulin (assay buffer) for one hour at 37 °C. 
After a new wash, the plates were ready for the assay. 
As standard, synthetic hPTH-(39-84) (Bachem AG, 
Bubendorf, Switzerland) was used diluted in assay bu-
ffer with 2% mouse serum. Aliquots of 100 µL of the 
standard samples (diluted 1:10 in assay buffer) or co-
lumn eluate were added, together with 100 µL of the 
rabbit polyclonal antibody in a 1:2000 dilution. After 
an overnight incubation followed by washing, 200 µL 
of a 1:1 000 dilution of europium-labeled (Europium 
labeling kit, PerkinElmer, Turku, Finland) monoclonal 
anti-rabbit IgG antibody, produced at our laboratories, 
was added. After an additional a two-hour incubation, 
plates were washed and time-resolved fluorescence 
was read. The assay presented a sensitivity of 50 ng/L 
(hPTH-(39-84)), an inter-assay CV of less than 10%, 
and a cross-reactivity (based on a 100% cross-reactivi-
ty with hPTH-(39-84)) of 52.8% with hPTH-(7-84), 
28.4% with hPTH-(1-84) and no cross-reactivity with 
the sequences 53-84, 44-68 and 69-84 of hPTH. The 
study of samples obtained from 30 adults with normal 
renal function showed values inferior to 500 ng/L.
Intact Pth assay
A monoclonal antibody-based immunofluorometric as-
say developed at our laboratory was employed. The assay 
employed two monoclonal antibodies, one amino-termi-
nal specific (labeled with europium) and one COOH-
terminal specific (the same H5P10 used in the long 
COOH assay). The assay had an analytical sensitivity of 
3 ng/L and a cross-reactivity of 50% with hPTH-(7-84) 
(PTH-(1-84) was used as reference). Upper normal ran-
ge for serum PTH using this assay was 46 ng/L (15).
Gel filtration chromatography
Serum samples were submitted to gel filtration chro-
matography on a Hiload Superdex 30, 1.6 x 60 cm 
column coupled to a FPLC Akta system (GE Health-
care). The gel column was chosen due to its fractio-
nation range (globular proteins) with V0 of < 10.000 
daltons. Serum samples of 0.5 mL were applied to the 
system, eluted (1 mL/min) with a PBS 0.05M, pH 7,2, 
0.15M NaCl buffer and 1.0 mL aliquots were collected 
for PTH analysis using both assays. Column calibration 
included blue dextran (V0), synthetic human PTH-(1-
84)(MW 9 425) was measured using the intact PTH 
assay, and synthetic human PTH-(39-84)(MW 4 962) 
was measured using the COOH immunometric assay. 
PTH measurement using the COOH and intact assays 
were performed in tubes number 40 to number 70 in 
all chromatographies. These tubes were chosen after 
calibration studies, and results of pilot serum samples 
(from patients with secondary hyperparathyroidism 
due to ESRD) indicated that they included all PTH 
forms detectable by both assays.
results
correlation between serum values of intact and 
cooh-terminal Pth assays
PTH values in serum samples from the 25 patients with 
ESRD ranged from 318 to 3.307 ng/L (mean ± sd: 1,769 
± 693 ng/L) using the intact assay and from 39,000 to 
232,300 ng/L (101,680 ± 45,330 ng/L) using the 
COOH assay. The coefficient of correlation (Pearson’s r) 
between the values obtained with the two methods was 
0.462 (p = 0.02). Data are presented in figure 1.
chromatography results 
In figure 2, the chromatography profile obtained with the 
serum of one representative patient with intact PTH of 
1.389 ng/L and COOH-terminal PTH of 118.450 ng/L 
was depicted. In the left Y-axis (ng/L), the PTH values 
measured in the eluate tubes, using both assays, are plot-
ted. The void volume of the column (V0) as well as the 
elution of PTH-(1-84) (MW 9 425 daltons) and PTH-
(39-84) (MW 4 982 daltons) are indicated by arrows, and 
the scale of MW (daltons) represented in the right Y-scale.
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Figure 2. Elution profile of a serum sample from a patient with ESRD loaded on a 
Hiload Superdex 30® 1.6 x 60 column. PTH contained in the elution tubes was 
measured using the long carboxyl-terminal (COOH) assay an intact PTH assay. The 
tubes which were blue dextran (V0), synthetic PTH-(1-84) (9425 daltons) and hPTH-
(39-84) (4982 daltons) eluted are also depicted. 
Figure 1. Correlation of values obtained (n = 25) from patients with ESRD using the 
long carboxyl-terminal (COOH) PTH assay and an intact PTH assay that recognizes 
predominantly PTH-(1-84) (r = 0.4619; p = 0.02).
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All immunoreactive PTH measured with the intact 
assay appeared in tubes 45 to 55, which is compatible with 
column calibration and assay specificity, since PTH (1-84) 
eluted with a peak around tube 50, as seen in figure 2. 
The elution of PTH forms detected with the COOH as-
say ranged from tube 45 to 65, encompassing forms with 
molecular weight from 10,000 to 4,500, according to 
the calibration profile. In order to evaluate the distribu-
tion of PTH forms recognized by the long COOH assay 
along the elution profile of the column, the elution profi-
le obtained with the COOH assay was arbitrarily divided 
into four quartiles. The first one included tubes 45 to 
50; the second, tubes 50 to 55; the third, from 55 to 60; 
and the fourth, from 60 to 65. The percent (mean ± sd) 
quartile distribution in the 25 samples was 7.1 ± 5.7 for 
the first quartile; 30.5 ± 10.8 for the second; 51.0 ± 11.1 
for the third; and 11.4 ± 6.4 for the forth. In accordance 
to the molecular weight distribution, the intact assay re-
cognized only PTH eluted in the first and second quarti-
les, and the COOH assay forms with MW ranging from 
10.000 to 4.500 daltons, included in the four quartiles, 
with higher values found in the third.
DIscussIon
PTH in circulation is quite heterogenous, with forms 
encompassing the complete 1-84 peptide to small frag-
ments consisting mainly of COOH sequences. These 
last ones are known to accumulate in patients with 
progressive degrees of renal failure since their metabo-
lic clearance depends heavily on glomerular filtration. 
The possibility that PTH fragments lacking the amino-
terminal sequence and, consequently, biological action 
via PTHR1 can have some biological action is not new 
(16,17). Experimental evidence of the presence of a 
COOH receptor is summing up (18,19). The clinical 
importance of measurement of these COOH fragments 
is still not clear but is based mainly on data provided by 
intact PTH assays that measure, besides the 1-84 form, 
only molecular forms with small amino-terminal dele-
tions, e.g. PTH (7-84) (20). The other methodological 
alternative is the use of old COOH specific competitive 
assays that measure almost all circulating forms, from 
the intact molecule to small COOH fragments (6). 
In the setting of ESRD, the question is particularly 
complex and is still subject to research and controversy 
(21,22). Our results confirm the presence of high levels 
of COOH fragments of significant molecular weight 
(> 4500 daltons) in serum samples obtained from pa-
tients with ESRD. These forms include the PTH 7-84 
(MW 8 781 daltons), but also include large quantities of 
COOH molecular form fragments, shorter than 7-84. 
One interesting observation is the profile of forms de-
tected by the COOH assay running from intact PTH to 
forms around 4500 daltons. These COOH PTH mo-
lecules have MW ranging from 8500 to 4500 and cor-
respond to deletions of 10 to 40 amino acids. They are 
represented in the chromatographic system employed 
by forms eluting in the third and fourth quartiles. These 
peptides are not recognized by the second-generation 
intact assays, have no activity in the PTH1R, but bind to 
COOH-terminal fragments of PTH in renal patients
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the C-PTH receptor with the same affinity of PTH-(1-
84) and (7-84) (12). One additional point that must be 
taken into account in the analysis of the elution profile 
is the specificity of the assay developed that spans from 
100% with PTH-(39-84) to 28% with PTH-(1-84).
The present findings are in accordance with those 
described by Zhang and cols. (23) in a recent publica-
tion, which used immunoaffinity and mass spectrome-
try to detect COOH fragments in samples from patients 
with ESRD. They described peptides ranging from 34-
84 to 45-84 to be the most abundant. These forms are, 
at least in part, detected by our COOH-specific assay. 
Methodological details could explain some potential di-
fferences in the detected forms, and can be related to the 
recognition of the antibodies used in the present assay or 
in the affinity purification used by Zhang and cols. (23).
The relative uniformity in the PTH-elution profile 
observed in the 25 patients with ESRD, confirmed by 
the low CV’s of the percent distribution in the percen-
tiles, indicate that it may be difficult to use this protocol 
to classify the bone disease presented by these patients. 
More studies correlating bone histomorphometry stu-
dies to PTH levels measured using assays like the one 
described here are necessary in order to define a poten-
tial clinical utility for the measurement of these long 
COOH terminal fragments of PTH in these patients.
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